PDS Biotechnology Corp (NAS:PDSB)
$ 1.64 -0.03 (-1.8%) Market Cap: 61.35 Mil Enterprise Value: 36.27 Mil PE Ratio: 0 PB Ratio: 2.74 GF Score: 31/100

Q3 2024 PDS Biotechnology Corp Earnings Call Transcript

Nov 14, 2024 / 01:30PM GMT
Release Date Price: $2.25 (-18.33%)
Operator

Good morning, ladies and gentlemen, and welcome to PDS Biotech's third-quarter 2024 results and clinical strategy update conference call. (Operator Instructions) I would now like to turn the conference over to Tom Johnson with LifeSci Advisors. Please go ahead, sir.

Thomas Johnson
LifeSci Advisors - Investor Relations

Thank you, operator, and good morning, everyone. Welcome to PDS Biotech's Third Quarter 2024 Results and Clinical Strategy Update Call. I'm joined on the call today by the following members of the company's management team: Dr. Frank Bedu-Addo, Chief Executive Officer; Dr. Kirk Shepard, Chief Medical Officer; and Lars Boesgaard, Chief Financial Officer.

Dr. Bedu-Addo will begin with an overview of the company's recent interactions with investors, investigators and others regarding its clinical development plans. Mr. Boesgaard will review our financial results for the third quarter, and Dr. Shepard will then join the call to help address questions from covering analysts.

As a reminder, during this call, we will be making forward

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot